Physician

Alan B Haratz, MD

According to 2025 Medicare claims, Alan Haratz, MD (NPI: 1336155688) practices nephrology in the Lakewood-New Brunswick, NJ market, with the plurality of this provider's patient population coming from Monmouth, NJ. This provider's primary affiliated billing organization is KIDNEY CARE CENTERS (NPI: 1689302424; TIN: 874435765) and primary practice location at 07724-4209.

Haratz's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 172 traditional Medicare patients, billed 19,593 HCPCS/CPT codes, and received $97,312 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 3,307 prescription claims across 217 beneficiaries totaling $618,714 in drug costs, led by Rayaldee (Calcifediol). DME data shows 140 claims. Open Payments data shows 59 records totaling $1,070. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved from a higher plateau to a lower plateau, from $298,116 to $97,312. Concurrently, Part D prescription costs did not follow a clear longitudinal pattern. In contrast, DME billing represents a smaller volume and moved up and down with repeated peaks and valleys, starting at $414 and ending at $4,800.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	789	12,493	$298,116
2016	766	13,533	$289,261
2017	751	8,758	$305,588
2018	554	9,745	$192,334
2019	224	5,769	$86,458
2020	213	7,072	$76,807
2021	211	6,849	$95,364
2022	212	9,639	$78,204
2023	184	11,146	$72,827
2024	172	19,593	$97,312

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	275	2,926	$533,384
2016	264	2,767	$496,890
2017	257	2,658	$590,445
2018	258	2,588	$451,069
2019	237	2,723	$401,482
2020	225	2,981	$376,584
2021	233	3,160	$425,588
2022	238	3,136	$401,474
2023	216	3,180	$508,943
2024	217	3,307	$618,714

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	251	$13,510
2016	N/R	192	$6,325
2017	N/R	179	$5,681
2018	N/R	131	$7,205
2019	N/R	103	$5,175
2020	N/R	134	$5,160
2021	N/R	76	$2,638
2022	N/R	99	$1,800
2023	N/R	139	$2,360
2024	N/R	140	$2,258

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	167	680	$99
G0008	Administration of influenza virus vaccine	22	22	$34
90656	Influenza vaccine, trivalent, split virus, preservative-free, 0.5 ml dosage	21	21	$22
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	126	207	$13
81002	Urinalysis, manual test	26	34	$3

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Rayaldee	Calcifediol	74	2,220	$89,936
Veltassa	Patiromer Calcium Sorbitex	61	2,685	$89,896
Ozempic	Semaglutide	48	1,568	$46,280
Farxiga	Dapagliflozin Propanediol	56	2,084	$39,763
Rybelsus	Semaglutide	28	1,170	$36,825

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	37	$659
J7507	Tacrolimus, immediate release, oral, 1 mg	N	N/R	37	$566
J7518	Mycophenolic acid, oral, 180 mg	N	N/R	16	$443
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	35	$439
J7517	Mycophenolate mofetil, oral, 250 mg	N	N/R	15	$152

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	59	$1,070	AstraZeneca Pharmaceuticals LP
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Alan B. Haratz, MD?

Tedicare shows public-source Medicare data for Alan B. Haratz, MD (NPI 1336155688), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Alan B. Haratz, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Alan B. Haratz, MD?

Alan B. Haratz, MD is linked to KIDNEY CARE CENTERS (billing NPI 1689302424) in the available physician profile data.

Does Alan B. Haratz, MD have Open Payments data?

Alan B. Haratz, MD has 59 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.